1 Essential Drug Trial Story for Indian Professionals
According to Press Monitor's tracking of Indian publications, this print media monitoring review highlights a pivotal story for Indian professionals: India's clinical trial ecosystem is falling behind China's at an alarming rate. This press review draws on today's front-page coverage to deliver media intelligence on the regulatory bottlenecks reshaping drug development in the country.
1. India Lags Behind China In Novel Drug Trials
A front-page report in Economic Times says India's clinical trial approval process has become painfully slow, with first-in-human trials taking six months or more to initiate. This regulatory bottleneck has caused innovative biotech companies to shift early-stage trials overseas, leading to a significant gap compared to China, which now conducts over one thousand such trials annually. The article argues that India must reform its system to leverage its scientific talent and manufacturing base to become a developer of novel medicines, not just a supplier.
Why it matters: India's approval process for first-in-human clinical trials has become painfully slow, taking six months or more to initiate. This regulatory bottleneck is causing innovative biotech companies to shift early-stage trials overseas, creating a significant gap compared to China, which now conducts over one thousand such trials annually.
Key detail: The article argues that India must reform its clinical trial system to leverage its scientific talent and manufacturing base to become a developer of novel medicines, not just a supplier. The news on drug trials comes as a wake-up call for policymakers and the pharmaceutical industry alike.
Source: Economic Times, Delhi, 2026-09-16, by Kiran Mazumdar-Shaw & Soham Sankaran
Next step: Stakeholders must push for regulatory reform to accelerate trial approvals and retain India's position as a global pharmaceutical hub.
Closing: Which reform — faster approvals or better infrastructure — would make the biggest difference for India's biotech sector? Share your thoughts below.
